Hypersensitivity syndrome due to drug exposure – ten years case review.
Craveiro N, Alves C, Fontes Ribeiro C,Batel Marques FJ
Pharmacoepidemiol Drug Saf 2011;20:S332-S333
2011
Níveis de causalidade imputados a reacções adversas a medicamentos em função do profissional notificador: potencial influência do acesso à informação clínica
Craveiro N, Alves C, Batel Marques F
Rev Port Farmacoter, 2010;2:89-93
2010
Desperdício de medicamentos no ambulatório em Portugal
Mendes Z, Crisóstomo S, Batel Marques F, Martins AP, Rodrigues V, Fontes Ribeiro C
Rev Port Clin Geral, 2010;26:12-20
2010
A exposição simultânea a vários medicamentos como factor de risco de reacções adversas graves
AF Macedo, C Alves, N Craveiro, F Batel Marques
Rev Port Farmacoter. 2010;2:163-166
2010
Differences in causality of adverse drug reactions according to the reports from different professional groups
Craveiro N, Alves C, Batel Marques FJ
Pharmacoepidemiol Drug Saf. 2010 Aug; 19(S) S179-180.
2010
Multiple drug exposure and severity of adverse drug reactions
Batel Marques FJ, Craveiro N, Macedo AF, Dinis P, Fontes-Ribeiro C, Caramona MM, Macedo T.
Pharmacoepidemiol Drug Saf. 2010 Aug; 19(S) S318-319
2010
Comparision of the rate and extent of absorption of nimesulide contained in tablets and in granules.
C. A. Fontes Ribeiro, C. Neta, F. Martins, H. Marques, J. Silva, T. R. A. Macedo
Comunicação em poster apresentada no 6th Congress of the European Association for Clinical Pharmacology and Therapeutics (Istambul, 24 a 28 de Junho de 2003)
Congress
2003
Centro de Estudos de Biodisponibilidade (CEB): Três Anos de estudos sobre a Qualidade dos Medicamentos.
C. A Fontes Ribeiro, C. Neta, F. Martins, H. Marques, J. Silva, T. R. A Macedo.
Poster apresentado no II Congresso de Investigação em Medicina, promovido pela Faculdade de Medicina da Universidade de Coimbra (Coimbra, 9 a 11 de Novembro de 2000) Publicação nas Actas do II Congresso de Investigação em Medicina, pp. 79, 2000
2000
Pre- and postjunctional effects of ATP and NPY on sympathetic control of human uterine artery
C. Cavadas, C.A. Fontes Ribeiro, C. Neta, J. Silva, S. Gulbenkian, M.T. Morgadinho, S.A.R. Silva, T.R.A Macedo
Poster with oral discussion in 3th Meeting of the Portuguese Society for Neuroscience (Espinho, December de 1996)
1996
Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects
Rocha JF, Vaz-da-Silva M, Almeida L, Falcão A, Nunes T, Santos AT, Martins F, Fontes-Ribeiro C, Macedo T, Soares-da-Silva P
Abstract
PURPOSE: Eslicarbazepine acetate (ESL) is a new voltage-gated sodium channel blocker currently in development for the treatment of neuropathic pain, including that of diabetic origin. The primary objective was to investigate the effect of ESL on the pharmacokinetics of metformin, a commonly used oral antidiabetic drug.
METHODS: Randomized, open-label, two-way crossover study in 20 healthy subjects. The volunteers received an 850 mg single-dose of metformin hydrochloride on two occasions – once as such and once after pre-treatment with an oral once-daily dose of ESL 1200 mg for 6 days – separated by a washout period of at least 2 weeks. The bioequivalence approach was used for assessing the effect of ESL on the pharmacokinetics of metformin. Test/Reference geometric mean ratios (GMR) and 90% confidence intervals (90% CI) were calculated for AUC0- yen, AUC0-12 and Cmax of metformin.
RESULTS: Test/Reference metformin GMR (90% CI) was 0.95 (0.86; 1.05) for AUC0- yen, 0.95 (0.88; 1.06) for AUC0-12, and 0.88 (0.77; 1.00) for Cmax. Formal bioequivalence could not be demonstrated for metformin Cmax. However, the extent of exposure to metformin, as reflected by AUC0-12 and AUC0- yen, allows the claim of bioequivalence since the 90% CI of the GMR fall within the pre-specified bioequivalence acceptance interval (0.80; 1.25).
CONCLUSION: Once-daily administration of ESL 1,200 mg had no relevant effect on the systemic exposure to metformin pharmacokinetics in healthy subjects.
Int J Clin Pharmacol Ther 2009 Apr; 47(4):255-61
2008
